
Topic 2: Power, replication, design

- Statistical power
- Sample size
- Pseudoreplication & Confounding variables
- Experimental design

Lectures 4 & 5




- Power of a study is the probability that it can distinguish an effect of a given size from random chance; Power = True positive rate = Sensitivity = Recall
- Most studies are underpowered → Waste of resources & Unethical

The power is the probability that the test correctly rejects the null hypothesis (H_0) when a specific alternative hypothesis (H_1) is true.


- Pr(reject H₀ | H₁ is true)
- H_1 has to be specific (cannot just be negation of H_0)
- The probability that it will yield a statistically significant outcome.

Power = $1 - \beta$: As power increases \rightarrow Probability of making type II error (β) decreases.




Power depends on:

- Size of the effect: larger the effect, easier it is to detect; standardized effect size is better
- Sample size: collecting more data → easier to detect small effects; relates to the
 efficiency of a given testing procedure, experimental design, or an estimator (sample
 size required for a given power)
- Statistical significance criterion: lesser conservative test (larger significance criterion) → more power
- Measurement error: counting cells vs. estimating level of fatigue/depression
- Experimental design: e.g. in a two-sample setting, optimal to have equal number




- Values sampled from $H_{\Delta} < x^*$ do not trigger rejection of H_{Ω} and occur at a rate β .
- Power (sensitivity; TRP) = 1β (blue area).
- Good to have low α (FPR) & low β (FNR), but:
 - \circ The α and β rates are inversely related: $\downarrow \alpha \to \uparrow \beta$ (& reduces power).




- Typically, $\alpha < \beta$: consequences of FP (in an extreme case, a retracted paper) are more serious than those of FN (a missed opportunity to publish).
- But, the balance between α and β depends on the objectives:
 - \circ If FP are subject to another round of testing but FN are discarded, β should be kept low.

Compromise between specificity and power




Specificity and power relationship




- Decreasing specificity (TNR) increases power (TPR)
- Can we improve our chance to detect increased expression from H_A (increase power) without compromising a (increasing FP)?

Impact of sample size on power



Impact of effect size on power



- Impact of sample size and effect size on power.
- In practice, because we estimate population σ from the samples, power is decreased and we need a slightly larger sample size to achieve the desired power.

Balancing sample size, effect size and power is critical to good study design.

- First, set the values of type I error (α) and power $(1-\beta)$ to be statistically adequate:
 - Traditionally 0.05 and 0.80, respectively.
- Then determine sample size (n) on the basis of the smallest effect we wish to measure.
 - \circ If the required sample size is too large \to may need to reassess objectives or more tightly control the experimental conditions to reduce the variance.
- When the power is low, only large effects can be detected, and negative results cannot be reliably interpreted.

- Clinical research (behavioral or drug treatments):
 - Need enough participants to represent all subtypes for which treatment might be used.
 - Some issues: lack reliable methods for diagnosis.
 - Rough rule of thumb: at least 100 people.
 - The actual number needed to find a valid effect depends on a range of factors, including the magnitude and frequency of the effect in the general population.

- Brain imaging studies:
 - Historically included 20 or fewer participants. In the past 10 years, closer to 100 participants.
 - Studies that aim to trace developmental trajectories should also track the same few individuals over time, scanning their brains at regular intervals, rather than examining a cross-section of people of different ages at different sites.

- Genetic studies (large no. of variants/genes, each making a small contribution):
 - Rare variants in coding regions: order of thousands of people.
 - Risk variants across the whole-genome: tens of thousands of individuals.
 - \blacksquare Millions of statistical tests, one per variant \rightarrow increases FPR.
 - GWAS: hundreds of thousands of individuals.
 - Common gene variants that contribute to the risk of a condition.

- Preclinical research:
 - Underpowered animal studies for decades (cost and ethical issues).
 - \circ Make up for their low numbers by analyzing a large number of cells or other samples from each animal \rightarrow 'pseudoreplication.'
 - \circ Can control lab animals' diets, ages and housing conditions, and scale doses or treatments by weight \rightarrow sample sizes on the order of 10 animals to be acceptable. Should \geq 15 per group to identify important biological effects.
 - \circ In the past few years, push for larger numbers in animal studies.

- Biomarker studies (physiological characteristics, such as patterns of eye movements, brain waves or activity, or blood chemistry):
 - Candidate biomarkers have often failed in subsequent studies.
 - Must draw samples from at least 100 individuals.
 - Clinical trials of biomarkers designed to flag people with disease $\rightarrow \ge 1,000$ participants. Researchers should also replicate the efficacy of a biomarker in an independent sample.
 - Some scientists are designing biomarker studies of thousands of participants that combine data from behavioral, imaging and genetic studies.

- Field trials:
 - Variables that are hard to control, and so must include hundreds of individuals to yield meaningful results.
 - Needs more than an appropriate number of participants.
 - Representative mix of sexes and ages.